Your browser doesn't support javascript.
loading
Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.
Ma, Yuxiang; Pan, Hui; Liu, Yu; Zhang, Yang; Hong, Shaodong; Huang, Jianjin; Weng, Shanshan; Yang, Yunpeng; Fang, Wenfeng; Huang, Yan; Xiao, Shanshan; Wang, Tao; Ding, Lieming; Cui, Lingling; Zhang, Li; Zhao, Hongyun.
Afiliação
  • Ma Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Pan H; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Liu Y; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zhang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Hong S; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Huang J; Department of Clinical Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Weng S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Yang Y; Department of Medical Oncology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China.
  • Fang W; Department of Medical Oncology, Zhejiang University School of Medicine Second Affiliated Hospital, Hangzhou, China.
  • Huang Y; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Xiao S; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Wang T; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Ding L; Department of R&D, Hangzhou Repugene Technology Co.,Ltd., Hangzhou, China.
  • Cui L; Department of R&D, Hangzhou Repugene Technology Co.,Ltd., Hangzhou, China.
  • Zhang L; Betta Pharmaceuticals Co., Ltd., China, Hangzhou, China.
  • Zhao H; Betta Pharmaceuticals Co., Ltd., China, Hangzhou, China.
J Thorac Dis ; 14(12): 4751-4762, 2022 Dec.
Article em En | MEDLINE | ID: mdl-36647478
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article